Han BiomedicalROCO:6999 +0.17%25 ROE % is 9.97% as of Dec. 2025, which is 6% below its 10-year median of 10.64. GuruFocus rates ROCO:6999 with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,248 Biotechnology companies, Han Biomedical ranks better than 87.5% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Han Biomedical's annualized net income for the quarter that ended in Dec. 2025 was NT$25.3 Mil. Han Biomedical's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was NT$253.9 Mil. Therefore, Han Biomedical's annualized ROE % for the quarter that ended in Dec. 2025 was 9.97%.
The historical rank and industry rank for Han Biomedical's ROE % or its related term are showing as below:
ROCO:6999'
s ROE % Range Over the Past 10 Years
Min: 7.52 Med: 10.64 Max: 10.95
Current: 8.94
During the past 5 years, Han Biomedical's highest ROE % was 10.95%. The lowest was 7.52%. And the median was 10.64%.
ROCO:6999's ROE % is ranked better than 87.5% of 1248
companies
in the Biotechnology industry
Industry Median: -38.26
vs ROCO:6999: 8.94
Han Biomedical (ROCO:6999) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Han Biomedical ROE % Related Terms
Han Biomedical ROE % Historical Data
* Premium members only.
The historical data trend for Han Biomedical's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Han Biomedical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Han Biomedical ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Han Biomedical's ROE % distribution charts can be found below:
* The bar in red indicates where Han Biomedical's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Han Biomedical (ROCO:6999) has a ROE % of 9.97% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Han Biomedical and its competitors. This is near median its historical median of 10.64. Over the past decade, Han Biomedical's ROE % has ranged from 7.52 to 10.95. According to the industry distribution chart, Han Biomedical ranks #156 out of 1248 companies in the Biotechnology industry, placing it in the top 12.5%.
Is Han Biomedical's ROE % too high?
Han Biomedical's current ROE % of 9.97% is near median its 10-year median of 10.64. Over the past 10 years, this metric has ranged from a low of 7.52 to a high of 10.95. Based on the distribution chart, Han Biomedical ranks #156 out of 1248 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Han Biomedical has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Han Biomedical's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Han Biomedical ranks #156 out of 1248 companies for ROE %. This places Han Biomedical in the top 13% of its industry — outperforming the majority of peers. Historically, Han Biomedical's own ROE % has ranged from 7.52 to 10.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Han Biomedical and its competitors. Han Biomedical's current ROE % is 9.97%, which is near median its own 10-year median of 10.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Han Biomedical stock overvalued right now?
Han Biomedical (ROCO:6999) has a current ROE % of 9.97%. The current ROE % is 9.97%, which is near median its 10-year median of 10.64. Han Biomedical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Han Biomedical (ROCO:6999), the current ROE % is 9.97% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6999 has been successfully added to your 